AlloNK's Phase 3 RCT in refractory RA tests whether Phase 2a's 71% ACR50 signal holds in a controlled, larger population with FDA-agreed endpoints

Bull

A clean trial launch with rapid enrollment of ~150 refractory RA patients would validate FDA alignment on ACR50 at 6 months as the primary endpoint and demonstrate operational readiness to execute a registrational program. If the Phase 2a signal of 71% ACR50 is replicated — against a rituximab monotherapy control arm — AlloNK would have a differentiated, potentially first-in-class deep B-cell depleting cell therapy with a compelling efficacy and safety profile in a high-unmet-need population, supporting accelerated review pathways including RMAT and Fast Track designations.

Bear

The most likely failure modes are enrollment difficulty given the narrow eligibility criteria (inadequate response to ≥2 biologic/targeted synthetic DMARDs), regression of the ACR50 rate toward the mean in a controlled RCT versus the uncontrolled Phase 2a basket signal, or a higher-than-expected adverse event rate at scale that undermines the outpatient community-setting narrative. Rituximab monotherapy could also outperform historical expectations in the control arm, compressing the observed treatment difference and making it harder to achieve statistical significance with a ~150-patient trial.